Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System
Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The ...
Monogram Orthopaedics announces 510(k) clearance for mBos TKA System
Monogram Technologies announced that the U.S. Food and Drug Administration has granted 510(k) clearance for its Monogram mBos TKA System. This ...
EXCLUSIVE: FDA Approves Monogram Technologies' mBôs TKA System For Knee Surgery
On Monday, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Monogram Technologies Inc.’s (NASDAQ:MGRM ...
Becker's Spine Review6h
Monogram earns FDA nod for knee replacement robot
Monogram Technologies earned FDA 510(k) clearance for its Monogram mBôs robot, according to a March 17 news release. The ...
MassDevice9h
FDA clears robotic knee surgery system from Monogram Technologies
Monogram Technologies (Nasdaq:MGRM) announced today that it received FDA 510(k) clearance for its mBôs total knee ...
Monogram Technologies Inc.: Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System
Market the Monogram mBôs TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act).The Company is Preparing for Commercialization and Evaluating Strategies ...
TipRanks on MSN15h
Monogram Orthopaedics Gains FDA Clearance for TKA System
Monogram Orthopaedics Inc ( ($MGRM) ) has issued an update. On March 17, 2025, Monogram Technologies Inc. announced that it received FDA 510(k) ...
All Penny Stocks (English) on MSN14h
FDA 510(k) Clearance Already Has This Micro Cap Off To The Races
A New York-based healthcare company is already turning heads during Monday’s premarket hours after it was announced that the ...
TMCnet14h
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025. MBX 1416 Phase 2 trial in patients with post-bariatric ...